Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
Xiu Liu,1 Xiaoting Ma,1 Kai Ou,1 Qi Wang,1,2 Lizhen Gao,1,3 Lin Yang1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 2Depa...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-03-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/real-world-results-of-raltitrexed-combined-with-s-1-and-bevacizumab-in-peer-reviewed-fulltext-article-CMAR |
| _version_ | 1797866270202265600 |
|---|---|
| author | Liu X Ma X Ou K Wang Q Gao L Yang L |
| author_facet | Liu X Ma X Ou K Wang Q Gao L Yang L |
| author_sort | Liu X |
| collection | DOAJ |
| description | Xiu Liu,1 Xiaoting Ma,1 Kai Ou,1 Qi Wang,1,2 Lizhen Gao,1,3 Lin Yang1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 2Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, People’s Republic of China; 3Department of Medical Oncology, Beijing Chaoyang Huanxing Cancer Hospital, Beijing, People’s Republic of ChinaCorrespondence: Lin Yang, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiyuanninli, Beijing, 10021, People’s Republic of China, Tel +86-10-87788118, Email linyangcicams@126.comPurpose: Treatment options for refractory metastatic colorectal cancer (CRC) are scarce. This retrospective study aimed to evaluate the efficacy and safety of raltitrexed combined with S-1 and bevacizumab in patients with heavily pretreated metastatic CRC in a clinical real-world setting.Patients and Methods: Records of patients with metastatic CRC refractory to standard therapies who initiated raltitrexed plus S-1 and bevacizumab from October 2017 to December 2021 were retrospectively reviewed at our institution. The study endpoints included median overall survival (OS), overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), and adverse events (AEs).Results: Forty-four patients with metastatic CRC, who had previously undergone standard chemotherapy received the regimen comprising raltitrexed plus S-1 and bevacizumab. As of March 2022, the median follow-up was 23.2 months (95% confidence interval 15.8− 30.6). The median OS and median PFS were 13.5 (95% CI 9.9– 17.1) and 4.7 months (95% CI 3.6– 5.8), respectively, with a 16-week PFS rate of 60.9%. Among 43 patients with measurable lesions, the ORR and DCR were 7.0% (3/43) and 65.1% (28/43), respectively. Patients without peritoneal metastases (P = 0.003, hazard ratio 0.160, 95% CI 0.048− 0.531), lower carcinoembryonic antigen level (≤ 42.8 ng/mL) (P = 0.039, HR 0.382, 95% CI 0.153− 0.952), and no previous treatment with both vascular endothelial growth factor inhibitors (VEGF) and S-1 (P = 0.020, HR 0.215, 95% CI 0.059− 0.785) had better OS. The incidence of any grade of treatment-related AEs was 88.6%, most of which were mild to moderate, and no treatment-related deaths occurred.Conclusion: Raltitrexed combined with S-1 and bevacizumab shows promising antitumor activity and safety and could be an alternative for patients with metastatic CRC who are refractory or intolerant to standard therapy.Keywords: refractory metastatic colorectal cancer, chemotherapy, target therapy, angiogenesis |
| first_indexed | 2024-04-09T23:21:19Z |
| format | Article |
| id | doaj.art-f4d8293c854a4b92b949397b5ca4d78e |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-09T23:21:19Z |
| publishDate | 2023-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-f4d8293c854a4b92b949397b5ca4d78e2023-03-21T18:11:20ZengDove Medical PressCancer Management and Research1179-13222023-03-01Volume 1527728982409Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal CancerLiu XMa XOu KWang QGao LYang LXiu Liu,1 Xiaoting Ma,1 Kai Ou,1 Qi Wang,1,2 Lizhen Gao,1,3 Lin Yang1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 2Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, People’s Republic of China; 3Department of Medical Oncology, Beijing Chaoyang Huanxing Cancer Hospital, Beijing, People’s Republic of ChinaCorrespondence: Lin Yang, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiyuanninli, Beijing, 10021, People’s Republic of China, Tel +86-10-87788118, Email linyangcicams@126.comPurpose: Treatment options for refractory metastatic colorectal cancer (CRC) are scarce. This retrospective study aimed to evaluate the efficacy and safety of raltitrexed combined with S-1 and bevacizumab in patients with heavily pretreated metastatic CRC in a clinical real-world setting.Patients and Methods: Records of patients with metastatic CRC refractory to standard therapies who initiated raltitrexed plus S-1 and bevacizumab from October 2017 to December 2021 were retrospectively reviewed at our institution. The study endpoints included median overall survival (OS), overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), and adverse events (AEs).Results: Forty-four patients with metastatic CRC, who had previously undergone standard chemotherapy received the regimen comprising raltitrexed plus S-1 and bevacizumab. As of March 2022, the median follow-up was 23.2 months (95% confidence interval 15.8− 30.6). The median OS and median PFS were 13.5 (95% CI 9.9– 17.1) and 4.7 months (95% CI 3.6– 5.8), respectively, with a 16-week PFS rate of 60.9%. Among 43 patients with measurable lesions, the ORR and DCR were 7.0% (3/43) and 65.1% (28/43), respectively. Patients without peritoneal metastases (P = 0.003, hazard ratio 0.160, 95% CI 0.048− 0.531), lower carcinoembryonic antigen level (≤ 42.8 ng/mL) (P = 0.039, HR 0.382, 95% CI 0.153− 0.952), and no previous treatment with both vascular endothelial growth factor inhibitors (VEGF) and S-1 (P = 0.020, HR 0.215, 95% CI 0.059− 0.785) had better OS. The incidence of any grade of treatment-related AEs was 88.6%, most of which were mild to moderate, and no treatment-related deaths occurred.Conclusion: Raltitrexed combined with S-1 and bevacizumab shows promising antitumor activity and safety and could be an alternative for patients with metastatic CRC who are refractory or intolerant to standard therapy.Keywords: refractory metastatic colorectal cancer, chemotherapy, target therapy, angiogenesishttps://www.dovepress.com/real-world-results-of-raltitrexed-combined-with-s-1-and-bevacizumab-in-peer-reviewed-fulltext-article-CMARrefractory metastatic colorectal cancerchemotherapytarget therapyangiogenesis |
| spellingShingle | Liu X Ma X Ou K Wang Q Gao L Yang L Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer Cancer Management and Research refractory metastatic colorectal cancer chemotherapy target therapy angiogenesis |
| title | Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer |
| title_full | Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer |
| title_fullStr | Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer |
| title_full_unstemmed | Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer |
| title_short | Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer |
| title_sort | real world results of raltitrexed combined with s 1 and bevacizumab in heavily pretreated metastatic colorectal cancer |
| topic | refractory metastatic colorectal cancer chemotherapy target therapy angiogenesis |
| url | https://www.dovepress.com/real-world-results-of-raltitrexed-combined-with-s-1-and-bevacizumab-in-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT liux realworldresultsofraltitrexedcombinedwiths1andbevacizumabinheavilypretreatedmetastaticcolorectalcancer AT max realworldresultsofraltitrexedcombinedwiths1andbevacizumabinheavilypretreatedmetastaticcolorectalcancer AT ouk realworldresultsofraltitrexedcombinedwiths1andbevacizumabinheavilypretreatedmetastaticcolorectalcancer AT wangq realworldresultsofraltitrexedcombinedwiths1andbevacizumabinheavilypretreatedmetastaticcolorectalcancer AT gaol realworldresultsofraltitrexedcombinedwiths1andbevacizumabinheavilypretreatedmetastaticcolorectalcancer AT yangl realworldresultsofraltitrexedcombinedwiths1andbevacizumabinheavilypretreatedmetastaticcolorectalcancer |